Lestaurtinib: a multi-targeted FLT3 inhibitor.

abstract：:Ofatumumab is a humanized second-generation monoclonal antibody with the affinity to a transmembrane protein CD20. In in vitro studies, it exhibits higher efficacy towards chronic lymphocytic leukemia (CLL) cells compared to rituximab, and it can be explained by the fact that its epitope on the target CD20 protein is ...

journal_title：Expert review of hematology

authors： Grosicki S

更新日期：2015-06-01 00:00:00

abstract：INTRODUCTION:Activation of the hemostatic system can occur in many clinical conditions. However, a systemic and strong activation of coagulation complicating clinical settings such as sepsis, trauma or malignant disease may result in the occurrence disseminated intravascular coagulation (DIC). Areas covered: This artic...

journal_title：Expert review of hematology

authors： Levi M,Sivapalaratnam S

更新日期：2018-08-01 00:00:00

abstract：OBJECTIVES:We analyzed hemoglobin (Hb) levels and degree of anemia in relation to genotype in patients with hemoglobin H (Hb H) disease, thereby providing a scientific basis for the prevention and treatment of Hb H disease in the Guangxi region of China. METHODS:Hb analysis was conducted in 615 patients using high per...

journal_title：Expert review of hematology

authors： Luo S,Chen X,Chen L,Zhong Q,Wang Q,Xu Z,Huang J,Yan T,Tang N

更新日期：2020-09-01 00:00:00

abstract：:Introduction: Oral anticoagulants (OACs) are established treatments to reduce thromboembolic risk in patients with atrial fibrillation (AF). Due to their mechanisms of action, they are associated with increased bleeding risk. Evaluation with bleeding risk scores may be useful to identify patients at high risk. However...

journal_title：Expert review of hematology

authors： Kozieł M,Ding WY,Kalarus Z,Lip GYH

更新日期：2019-10-01 00:00:00

abstract：INTRODUCTION:Recent advances and drug approvals in the last decade have substantially changed the landscape of relapsed and refractory multiple myeloma (RRMM), which not only improved outcomes for patients but also increased complexity of treatment decisions. The approvals are based on randomized studies of novel agent...

journal_title：Expert review of hematology

authors： Sanchez L,Barley K,Richter J,Franz J,Cho HJ,Jagannath S,Madduri D,Parekh S,Richard S,Chari A

更新日期：2020-09-01 00:00:00

abstract：:It is well known that the risk of venous thromboembolism is increased after surgery; however, specific data on how long this risk lasts or how the risk varies by type of surgery is limited. The Million Women Study is a population-based prospective study that recruited 1.3 million women through the National Health Serv...

journal_title：Expert review of hematology

authors： Faltas B

更新日期：2010-04-01 00:00:00

abstract：:Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: acute, lymphoma, chronic and smoldering type. Although the prognosis of chronic and smoldering-type ATL is relatively good,...

journal_title：Expert review of hematology

authors： Tanosaki R,Tobinai K

更新日期：2010-12-01 00:00:00

abstract：INTRODUCTION:Purine analogs made dramatic improvements for patients with hairy cell leukemia (HCL), but patients often relapse, require multiple treatments, and may become refractory. Major developments in treatment of relapsed/refractory HCL occurred with discovery of disease biology. New agents increase the complexit...

journal_title：Expert review of hematology

authors： Chihara D,Kreitman RJ

更新日期：2020-10-01 00:00:00

abstract：:Adult immune thrombocytopenia was previously considered a benign disease affecting young people and with a low risk of severe bleeding. This view was challenged by studies published during the past decade, as the median age of adult immune thrombocytopenia patients has been found to be 55-60 years and the incidence in...

journal_title：Expert review of hematology

authors： Frederiksen H,Christiansen CF,Nørgaard M

更新日期：2012-04-01 00:00:00

abstract：:Hemopoietic stem-cell transplant patients may require intensive blood component support. Complications of transfusions include transmission of viral and bacterial infections, transfusion-associated graft-versus-host disease and transfusion-related acute lung injury. Alloimmunization to red cell antigens may cause diff...

journal_title：Expert review of hematology

authors： Radia R,Pamphilon D

更新日期：2011-04-01 00:00:00

abstract：INTRODUCTION:Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. Despite the indolent nature of CLL/SLL, treatment is likely indicated in a patients' lifetime. Recent changes in the t...

journal_title：Expert review of hematology

authors： Tees MT,Flinn IW

更新日期：2017-02-01 00:00:00

abstract：:Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct...

journal_title：Expert review of hematology

authors： Figueiredo L,Cole PD,Drachtman RA

更新日期：2016-03-01 00:00:00

abstract：:Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that ...

journal_title：Expert review of hematology

authors： Al-Hussaini M,DiPersio JF

更新日期：2014-08-01 00:00:00

abstract：INTRODUCTION:Haploidentical stem cell transplantation (Haplo-SCT) is currently a suitable alternative worldwide for patients with hematological diseases, who lack human leukocyte antigen (HLA)-matched siblings or unrelated donors. Areas covered: This review summarizes the advancements in Haplo-SCT in recent years, prim...

journal_title：Expert review of hematology

authors： Sun YQ,Chang YJ,Huang XJ

更新日期：2018-04-01 00:00:00

abstract：:β-thalassemias are caused by nearly 300 mutations of the β-globin gene, leading to a low or absent production of adult hemoglobin (HbA). Two major therapeutic approaches have recently been proposed: gene therapy and induction of fetal hemoglobin (HbF) with the objective of achieving clinically relevant levels of Hbs. ...

journal_title：Expert review of hematology

authors： Breda L,Rivella S,Zuccato C,Gambari R

更新日期：2013-06-01 00:00:00

abstract：INTRODUCTION:Most patients with Hodgkin lymphoma (HL) enjoy durable remissions following front-line treatment but 30% of patients are refractory or relapse after first line therapy. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) can cure an additional 50-55% of relapsing patients but new t...

journal_title：Expert review of hematology

authors： Donato EM,Fernández-Zarzoso M,De La Rubia J

更新日期：2017-05-01 00:00:00

abstract：:Despite significant improvements in treatment modalities over the 10 years, the clinical course of patients with follicular lymphoma (FL) remains heterogeneous. Thus, prognostic indexes are still required to direct treatment choices and for the design of clinical trials. Investigators have conducted a variety of studi...

journal_title：Expert review of hematology

authors： Luminari S,Cox MC,Montanini A,Federico M

更新日期：2009-10-01 00:00:00

abstract：INTRODUCTION:Immune surveillance is the dynamic process whereby the immune system identifies and kills tumor cells based on their aberrant expression of stress-related surface molecules or presentation of tumor neoantigens. It plays a crucial role in controlling the initiation and progression of hematologic cancers suc...

journal_title：Expert review of hematology

authors： Nesic M,El-Galaly TC,Bøgsted M,Pedersen IS,Dybkær K

更新日期：2020-06-01 00:00:00

abstract：:Here we review the recent literature on Hemophilia gene transfer/therapy. Gene therapy is one of several new technologies being developed as a treatment for bleeding disorders. We will discuss current and pending clinical efforts and attempt to relate how the field is trending. In doing so, we will focus on the use of...

journal_title：Expert review of hematology

authors： Ward P,Walsh CE

更新日期：2016-07-01 00:00:00

abstract：:The introduction of bortezomib, a first-generation proteasome inhibitor, changed the standard-of-care for newly diagnosed and relapsed multiple myeloma patients. The next generation of proteasome inhibitors, such as carfilzomib, provides a novel pharmacokinetic and pharmacodynamic profile. In vitro data suggest a more...

journal_title：Expert review of hematology

authors： Khan RZ,Badros A

更新日期：2012-08-01 00:00:00

abstract：:Over two-thirds of newly diagnosed multiple myeloma are over 65 years. The treatment goals for the non-transplant-eligible patients should be to prolong survival by achieving the best response, while ensuring quality of life. New upfront treatment combinations based on first generation of novel proteasome inhibitors a...

journal_title：Expert review of hematology

authors： Mateos MV,Leleu X,Palumbo A,San Miguel JF

更新日期：2014-02-01 00:00:00

abstract：INTRODUCTION:Diffuse large B-cell lymphoma (DLBCL) is a molecularly heterogeneous disease defined by different cellular origins and mechanisms of oncogenic activation. Approximately 10% of DLBCL cases harbor a MYC rearrangement and this has been associated with a more aggressive clinical course following standard thera...

journal_title：Expert review of hematology

authors： Burotto M,Berkovits A,Dunleavy K

更新日期：2016-07-01 00:00:00

abstract：INTRODUCTION:Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia that carries poor prognosis in adults especially in the setting of high risk cytogenetics and relapsed/refractory (R/R) disease. Advancements in immunotherapy have led to the development of several monoclonal antibodies (MoAbs) and chimer...

journal_title：Expert review of hematology

authors： Valecha GK,Ibrahim U,Ghanem S,Asti D,Atallah JP,Terjanian T

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:Hypogonadism is the most frequently reported endocrine complication, affecting 40%-80% of thalassemia major (TM) patients. The prevalence and severity of hypogonadism in TM varies among studies, depending on patients' age, genotype, transfusion frequency and starting age and efficiency of iron chelation. A...

journal_title：Expert review of hematology

authors： De Sanctis V,Soliman AT,Elsedfy H,Di Maio S,Canatan D,Soliman N,Karimi M,Kattamis C

更新日期：2017-12-01 00:00:00

abstract：INTRODUCTION:Treatment of elderly patients with acute leukemia is challenging. Older age is associated with increased risk of treatment-related toxicity. Currently, no consensus exists regarding optimal therapy in this patient population. Areas covered: The following review is a comprehensive summary of various therape...

journal_title：Expert review of hematology

authors： Thomas X

更新日期：2017-11-01 00:00:00

abstract：INTRODUCTION:Multiple myeloma (MM) is characterized by notable inter-patient and intra-clonal heterogeneity that is gradually decoded over the last decade. Despite the deeper and better understanding of its biology and the development of novel therapeutic strategies that have prolonged overall survival, MM still retain...

journal_title：Expert review of hematology

authors： Ziogas DC,Dimopoulos MA,Kastritis E

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:Guidelines provide recommendations on the management of multiple myeloma (MM), but there are no standard algorithms for the choice and sequencing of treatments. As a result, there is widespread variation in the interpretation and implementation of these guidelines. Areas covered: This review will cover: th...

journal_title：Expert review of hematology

authors： Cavo M,Terpos E,Bargay J,Einsele H,Cavet J,Greil R,de Wit E

更新日期：2018-03-01 00:00:00

abstract：:Iron overload is frequently observed in patients with hematologic diseases before and after allogeneic stem-cell transplantation because they usually receive multiple red blood cell transfusions. Elevated pretransplant serum ferritin levels, which are widely used as indicators of body iron status, are significantly as...

journal_title：Expert review of hematology

authors： Kanda J,Kawabata H,Chao NJ

更新日期：2011-02-01 00:00:00

abstract：:Recombinant IFN-α (rIFN-α) induces complete hematologic remissions in patients with myeloproliferative neoplasms (MPNs), but its use has been limited by side effects owing to the relatively high doses used. Now, low-dose rIFN-α is stressed, starting relatively early in the course of the MPNs. In polycythemia vera, thi...

journal_title：Expert review of hematology

authors： Silver RT,Kiladjian JJ,Hasselbalch HC

更新日期：2013-02-01 00:00:00

abstract：:Objectives: CD43 can be useful in routine flow cytometry. We conducted a systematic review aiming to describe when CD43 is used by flow cytometry in malignant hematology and to determine its value in these settings. Methods: Systematic review of MEDLINE (search 'CD43' AND 'flow cytometry,' starting in 2010). Results: ...

journal_title：Expert review of hematology

authors： Sorigue M

更新日期：2021-01-01 00:00:00